Immunoglobulin A Nephropathy Clinical Trials in London
4 recruitingLondon, United Kingdom
Showing 1–4 of 4 trials
Recruiting
Phase 2
A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy
Kidney DiseasesImmune System DiseasesAutoimmune Diseases+3 more
University of Leicester24 enrolled6 locationsNCT04663204
Recruiting
Phase 2
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Alport SyndromeFocal Segmental GlomerulosclerosisImmunoglobulin A Nephropathy+2 more
Travere Therapeutics, Inc.67 enrolled47 locationsNCT05003986
Recruiting
Phase 3
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A NephropathyIgAN
Alexion Pharmaceuticals, Inc.510 enrolled267 locationsNCT06291376
Recruiting
Phase 2
Study of WAL0921 in Patients With Glomerular Kidney Diseases
Diabetic NephropathiesPrimary Focal Segmental GlomerulosclerosisMinimal Change Disease+2 more
Walden Biosciences96 enrolled50 locationsNCT06466135